[Gastrointestinal side effects of apremilast : Characterization and management]. / Gastrointestinale Beschwerden unter Apremilast : Charakterisierung und Management.
Hautarzt
; 70(5): 354-362, 2019 May.
Article
em De
| MEDLINE
| ID: mdl-30937481
ABSTRACT
Apremilast is an oral inhibitor of phosphodiesterase-4 (PDE4) that is licensed for the second-line treatment of psoriasis and psoriatic arthritis. Data from several phase III clinical trials and real-world studies showed a good benefit-risk profile, with diarrhea and nausea as the most common adverse events. Diarrhea and nausea most frequently occurred during the first month of treatment. In most cases, they were mild or moderate in severity and tended to resolve over time with continued dosing and without intervention. In this review we summarize available data on gastrointestinal side effects of apremilast in patients with psoriasis and psoriasis arthritis and provide practical strategies for managing these symptoms.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Talidomida
/
Artrite Psoriásica
/
Anti-Inflamatórios não Esteroides
/
Inibidores da Fosfodiesterase 4
/
Gastroenteropatias
Limite:
Humans
Idioma:
De
Revista:
Hautarzt
Ano de publicação:
2019
Tipo de documento:
Article